Enterosgel with licorice flavor

INSTRUCTION FOR MEDICAL USE OF THE MEDICINAL PRODUCT ENTEROSGEL WITH SWEET FLAVOR (ENTEROSGELUM DULCIS)

Composition:

Active ingredient: 100 g contains methylsilicic acid hydrogel – 69.9 g;

Excipients: sodium saccharin dihydrate, sodium cyclamate, purified water.

Pharmaceutical form. Oral paste.

Main physicochemical properties: homogeneous white, odorless, paste-like mass.

Pharmacotherapeutic group.
Enterosorbents. ATC code A07BC.

Pharmacological properties.

Pharmacodynamics.

Enterosgel is an inert silicon-organic compound. When administered, it exhibits sorption activity. The medicinal product effectively adsorbs medium-sized toxic molecules of exogenous and endogenous origin, products of incomplete metabolism, incorporated radionuclides, and naturally eliminates them from the body. Enterosgel alleviates symptoms of intoxication, improves intestinal function, enhances detoxification functions of the liver and kidneys, and normalizes blood and urine parameters.

Pharmacokinetics.

By coating the mucous membranes of the stomach and intestines, Enterosgel protects them from erosive processes and promotes enhancement of local immunity. Enterosgel is not absorbed from the gastrointestinal tract and undergoes neither metabolic nor chemical transformations.

Clinical characteristics.

Indications.

Detoxification of the body in chronic renal failure caused by pyelonephritis, polycystic kidney disease, nephrolithiasis; in toxic hepatitis, viral hepatitis A and B, cholecystitis, liver cirrhosis, cholestasis of various etiologies, gastritis with reduced acidity, enterocolitis, colitis, diarrhea; in alcohol and drug intoxication; in allergic reactions, skin diseases (diatheses, neurodermatitis); in burn disease; in purulent-septic processes; in toxemias of the first half of pregnancy; as part of complex therapy for intestinal dysbiosis.

Contraindications.

Acute intestinal obstruction. Hypersensitivity to the components of the drug. Individual intolerance to the components of the drug.

Interaction with other medicinal products and other forms of interaction.

The drug may reduce the effect of other medicinal products taken concurrently. Concomitant use with bile acid sequestrants, such as cholestyramine, is not recommended, as it increases the risk of constipation.

The medicinal product should not be used together with silver-containing preparations.

Instructions for use.

The drug should be taken according to these instructions. Provided the recommended administration regimen is followed (Enterosgel and other medicinal products should be taken with an interval of 1.5–2 hours), the drug may be used in combination therapy with other medicinal and prophylactic agents, including prebiotics and probiotics (bifidum-, lactobacilli), phytopreparations, adaptogens, and immunomodulators.

Use during pregnancy or breastfeeding.

The drug may be used during pregnancy or breastfeeding. Its use should be limited in pregnant women who are prone to constipation.

Effect on the ability to drive vehicles or operate machinery.

No effect.

Method of Administration and Dosage.

Take orally 2–3 times a day, 1.5–2 hours before or 2 hours after meals or administration of other medications, washing down with sufficient amount of water.

For adults and children aged 14 years and older, the single dose is 15 g (tablespoonful), daily dose is 45 g.

For children from birth to 3 years of age, the single dose is 5 g (teaspoonful), daily dose is 10 g; for children aged 3 to 5 years, the single dose is 5 g, daily dose is 15 g; for children aged 5 to 14 years, the single dose is 10 g (dessert spoonful), daily dose is 30 g.

Treatment duration is 7 to 14 days. In severe cases, double the single dose during the first three days. In chronic conditions (chronic renal failure, liver cirrhosis), prolonged use of the drug is possible.

Children.

The drug can be used in children from birth. For children under 2 years of age, the single dose may be mixed with a small amount of water before administration.

Overdose.

Cases of overdose have not been reported. In case of overdose, adverse effects may be intensified.

Side effects.

Dyspeptic symptoms may occur during administration of the drug. Constipation may develop during the first days of treatment. To prevent constipation, patients prone to this condition are recommended to use a cleansing enema at night or take laxatives (lactulose, sodium picosulfate) during the first two days of treatment. Hypersensitivity reactions are possible. Individual intolerance to the components of the drug may occur.

Shelf life. 2 years.

Storage conditions.

Store out of reach of children. Store in the original packaging at a temperature not exceeding 25 °C. Do not freeze. After opening the package, store under the same conditions in tightly closed containers.

Packaging.

135 g, 270 g, 405 g in a plastic container; 1 container per cardboard box; 15 g in a sachet; 10 or 20 sachets per cardboard box; 90 g or 225 g in a tube; 1 tube per cardboard box.

Availability. Over-the-counter.

Manufacturer.

JSC "EOP "KREOMA-PHARM".

Manufacturer's address and place of business.

3 Radyscheva St., Kyiv, Ukraine.